Scott Gottlieb

Dr. Scott Gottlieb, MD, is an Independent Director at UnitedHealth Group, Inc., an Independent Chairman at Illumina, Inc., an Independent Director at Tempus AI, Inc., an Independent Director at Pfizer Inc., a Partner at New Enterprise Associates, Inc., a Special Partner at NEA Management Co. LLC and a Member at National Academy of Medicine (United States).
He is on the Board of Directors at UnitedHealth Group, Inc., Xaira Therapeutics, Inc., Comanche Biopharma Corp., Tempus AI, Inc., Aetion, Inc., Pfizer Inc., National Resilience, Inc., The Mount Sinai Health System, Inc., The Mount Sinai Medical Center, Inc. and Wesleyan University.
Dr. Gottlieb was previously employed as a Commissioner by US Food & Drug Administration, an Independent Member of the Board of Directors by Daiichi Sankyo, Inc., a Member of the Board of Directors by Gradalis, Inc., a Managing Director by T.R.
Winston & Co. LLC, a Member of the Board of Directors by Aptiv Solutions, Inc., an Independent Member of the Board of Directors by American Pathology Partners, Inc., an Independent Member of the Board of Directors by Bravo Health, Inc., an Independent Director by CombiMatrix Corp., a Member of the Board of Directors by MedAvante, Inc., an Independent Member of the Board of Directors by Molecular Insight Pharmaceuticals, Inc., a Deputy Commissioner-Medical & Scientific Affairs by US Food & Drug Administration, a Senior Adviser to the Administrator by Centers for Medicare & Medicaid Services (US), and an Analyst by Alex.
Brown & Sons, Inc. He also served on the board at EMI, Inc., Tolero Pharmaceuticals, Inc., Aseko, Inc. and Targeted Medical Pharma, Inc. He received his undergraduate degree from Wesleyan University and a doctorate degree from Icahn School of Medicine at Mount Sinai.